LEP and obesity due to melanocortin 4 receptor deficiency: A clinical trial (NCT05494112) is currently underway to evaluate the efficacy of Celastrol in treating obesity by restoring leptin sensitivity [48] (Table 1), which may have important implications for neurodegenerative diseases in the future.